These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30341231)

  • 21. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
    Musso G; Cassader M; Paschetta E; Gambino R
    JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
    Zaitone S; Hassan N; El-Orabi N; El-Awady el-S
    Eur J Pharmacol; 2011 Jul; 662(1-3):70-7. PubMed ID: 21549113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.
    Musso G; Gambino R; Cassader M; Pagano G
    Hepatology; 2010 Jul; 52(1):79-104. PubMed ID: 20578268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH).
    Surapaneni KM; Priya VV; Mallika J
    Eur Rev Med Pharmacol Sci; 2014; 18(18):2736-41. PubMed ID: 25317811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.
    Tang W; Xu Q; Hong T; Tong G; Feng W; Shen S; Bi Y; Zhu D
    Diabetes Metab Res Rev; 2016 Feb; 32(2):200-16. PubMed ID: 26381272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM; Sterling RK
    Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease: new treatments.
    Hardy T; Anstee QM; Day CP
    Curr Opin Gastroenterol; 2015 May; 31(3):175-83. PubMed ID: 25774446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.
    Majzoub AM; Nayfeh T; Barnard A; Munaganuru N; Dave S; Singh S; Murad MH; Loomba R
    Aliment Pharmacol Ther; 2021 Oct; 54(7):880-889. PubMed ID: 34435378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Kalogirou MS; Patoulias D; Haidich AB; Akriviadis E; Sinakos E
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101568. PubMed ID: 33309563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
    Cicero AFG; Colletti A; Bellentani S
    Nutrients; 2018 Aug; 10(9):. PubMed ID: 30142943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current treatment for non-alcoholic fatty liver disease.
    Moctezuma-Velázquez C
    Rev Gastroenterol Mex (Engl Ed); 2018; 83(2):125-133. PubMed ID: 29655574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.
    Oh H; Jun DW; Saeed WK; Nguyen MH
    Clin Mol Hepatol; 2016 Sep; 22(3):327-335. PubMed ID: 27729634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF; Sun Y; Shen L
    Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
    Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effects of Combined Vitamin E and C for Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Poonyam P; Kritsanaviparkporn C; Chommaitree P; Soodcharoen A
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2891-2899. PubMed ID: 36172650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials.
    Koutnikova H; Genser B; Monteiro-Sepulveda M; Faurie JM; Rizkalla S; Schrezenmeir J; Clément K
    BMJ Open; 2019 Mar; 9(3):e017995. PubMed ID: 30928918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.